Efficacy of CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2 − breast cancer: an umbrella review

ConclusionsBased on current evidence, CDK4/6 inhibitors combined with ET have great confidence in improving PFS, OS, ORR, and CBR outcomes in patients with ABC, which provides more rational and valid evidence-based medicine for CDK4/6 inhibitor promotion and clinical decision support.

Source: Journal of Cancer Research and Clinical Oncology - January 19, 2024 Category: Cancer & Oncology Source Type: research